Ser565

Site Information
QGEALDssQKkTkNK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18011838

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Disease tissue studied:	cervical cancer ( 4 ) , cervical adenocarcinoma ( 4 ) , leukemia ( 2 ) , acute myelogenous leukemia ( 2 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 1 , 3 , 5 ) , HeLa S3 (cervical) ( 4 ) , KG-1 (myeloid) ( 2 )

Upstream Regulation
Treatments:	nocodazole ( 4 )

References
1	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
2	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
3	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
4	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
5	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info